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miR-29c plays a suppressive role in breast
cancer by targeting the TIMP3/STAT1/
FOXO1 pathway
Wan Li1,2†, Jie Yi3†, Xiangjin Zheng1,2, Shiwei Liu4, Weiqi Fu1,2, Liwen Ren1,2, Li Li2, Dave S. B. Hoon5,
Jinhua Wang1,2* and Guanhua Du1,2*

Abstract
Background: miR-29c has been associated with the progression of many cancers. However, the function and
mechanism of miR-29c have not been well investigated in breast cancers.
Methods: Real-time quantitative PCR was used to assess expression of miR-29c and DNMT3B mRNA. Western blot
and immunochemistry were used to examine the expression of DNA methyltransferase 3B (DNMT3B) protein
in breast cancer cells and tissues. The functional roles of miR-29c in breast cancer cells such as proliferation, migration,
invasion, colony formation, and 3D growth were evaluated using MTT, transwell chambers, soft agar, and 3D Matrigel
culture, respectively. In addition, the luciferase reporter assay was used to check if miR-29c binds the 3′UTR of DNMT3B.
The effects of miR-29c on the DNMT3B/TIMP3/STAT1/FOXO1 pathway were also examined using Western blot
and methyl-specific qPCR. The specific inhibitor of STAT1, fludarabine, was used to further check the mechanism
of miR-29c function in breast cancer cells. Studies on cell functions were carried out in DNMT3B siRNA cell lines.
Results: The expression of miR-29c was decreased with the progression of breast cancers and was closely associated
with an overall survival rate of patients. Overexpression of miR-29c inhibited the proliferation, migration, invasion,
colony formation, and growth in 3D Matrigel while knockdown of miR-29c promoted these processes in breast cancer
cells. In addition, miR-29c was found to bind 3′UTR of DNMT3B and inhibits the expression of DNMT3B, which was
elevated in breast cancers. Moreover, the protein level of TIMP3 was reduced whereas methylation of TIMP3 was
increased in miR-29c knockdown cells compared to control. On the contrary, the protein level of TIMP3 was increased
whereas methylation of TIMP3 was reduced in miR-29c-overexpressing cells compared to control. Knockdown of
DNMT3B reduced the proliferation, migration, and invasion of breast cancer cell lines. Finally, our results showed that
miR-29c exerted its function in breast cancers by regulating the TIMP3/STAT1/FOXO1 pathway.
Conclusion: The results suggest that miR-29c plays a significant role in suppressing the progression of breast cancers
and that miR-29c may be used as a biomarker of breast cancers.
Keywords: Breast cancer, miR-29c, DNMT3B, methylation, and STAT1/FOXO1
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Background
Cancer is a major public health problem worldwide and
is the second leading cause of death in China and the
USA [1, 2]. Breast cancer is the most commonly diagnosed
female cancer in the world. It is extremely important to elucidate the mechanisms of breast cancer development and
progression and to facilitate early diagnosis.
In the last decades, studies have focused on the epigenetic changes in the development and progression of
breast cancers. Epigenetic changes include DNA methylation, histone modifications, abnormal expression of
non-coding RNAs, and chromatin remodeling [3]. microRNAs are conserved small non-coding RNAs that regulate
gene expression at the translational or post-transcriptional
level by repressing or degrading target messenger RNAs
[4]. miRNAs are widely expressed in normal tissues and
are often miss-regulated in disease states [5]. There is
increasing evidence that miRNAs play critical roles in
tumorigenesis by functioning as oncogenes or tumor
suppressors [6]. Recently, miRNAs have emerged as
novel biomarkers in the diagnosis, therapy, and prevention of breast cancer. The miR-29 family consists of
miR-29a, miR-29b, and miR-29c. They regulate a series
of biological processes, including cell proliferation [7],
epigenetic modification [8], intracellular signaling [9],
and cell movement [10]. The expression of miR-29c is
decreased in many cancers including hepatocellular
carcinoma [11], leukemia [12], glioma [13], bladder cancer [14], gastric carcinoma [15], breast cancer [16, 17],
and melanoma [18].
DNA methylation is an epigenetic modification that is
involved in many of the vital biological functions, such
as embryonic development [19], regulation of gene
expression [20], imprinting [21], and X-chromosome
inactivation [22]. DNMT3B, one of the major DNA
methyltransferases, is thought to function in de novo
methylation of DNA [23]. DNA methylation of promoter
CpG dinucleotides is associated with the suppression of
gene expression in cancers. Several studies have shown
that DNMT3B is frequently upregulated and plays an
important role in many cancers [24, 25]. It is unclear if
there is an association between miR-29c and DNMT3B,
and what regulatory mechanisms of miR-29c and
DNMT3B occur in breast cancer cells.
In this study, we investigated the expression of miR-29c
in breast cancer at different clinicopathological stages to
identify any association with clinical staging and overall
patient survival. We also studied the effects of miR-29c
overexpression in cell growth, migration, invasion, and
colony formation. The binding of miR-29c to the 3′UTR
of DNMT3B was examined, and the effects of knockdown
of DNMT3B on proliferation, migration, and invasion
were investigated in breast cancer cell lines. The expression of DNMT3B, TIMP3, STAT1, and FOXO1 was
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assessed by Western blot in miR-29c overexpression cells,
miR-29c knockdown cells, and DNMT3B siRNA cells. Together, the results demonstrate a suppressive role of miR29c by targeting the TIMP3/STAT1/FOXO1 pathway in
breast cancer cell proliferation, migration and invasion, and
suggest that the loss of miR-29c might be a novel biomarker related to the progression of breast cancer.

Methods
Cell culture

MCF-7, MDA-MB-231, and MDA-MB-436 breast cancer cell lines were purchased from the Cell Bank of the
Chinese Academy of Sciences (Beijing, China). All cells
lines were authenticated using the Short Tandem Repeat
(STR) method, performed by this cell bank. MCF-7 cells
were maintained in RPMI 1640 (Thermo Fisher Scientific,
Carlsbad, CA) while MDA-MB-231 and MDA-MB-436
cells were cultured in Dulbecco’s modified Eagle medium
(DMEM, Thermo Fisher Scientific). The complete culture
medium was prepared by adding 10% fetal bovine serum
(FBS, Thermo Fischer Scientific). Cells were cultured at
37 °C in a humidified incubator containing 5% CO2.
For drug treatment, cells were treated with fludarabine
2 μM, a STAT1 inhibitor for 24 h and used in specific
cell culture experiments.
Breast cancer tissues

The use of human tissues was approved by the Institutional
Review Board at the Peking Union Medical College
Hospital, Beijing, China. Breast cancer tissues were diagnosed at a different stage and obtained from the Peking
Union Medical College Hospital Pathology Department.
miRNA was extracted from serums

Serum samples were collected from 20 healthy females
and 79 breast cancer patients at a different stage. The
use of serums was also approved by the Institutional
Review Board at the Peking Union Medical College
Hospital, Beijing, China. Cell-free total RNA including
primary miRNA and other small RNA was purified from
serum by using miRNeasy Serum/Plasma Kit (Cat No
217184, QIAGEN, Hilden, China).
Transfection

MCF-7, MDA-MB-231, and MDA-MB-436 cells were
plated in 60-mm dishes at 80% confluence before transfection. Anti-miR-29c (Cat# AM17000, Thermo Fisher
Scientific, Waltham, MA USA) was transfected into MCF7 cells, and miR-29c mimic (Cat# 4464066, Thermo Fisher
Scientific, Waltham, MA, USA) was transfected into
MDA-MB-231 and MDA-MB-436 cells using the Lipofectamine™ 3000 transfection reagent (Invitrogen, Grand
Island, NY). After transfection for 48 h, the cells were collected and used for the in vitro functional analysis.
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MDA-MB-231 miR-29c cells (after transfection of miR29c mimic for 48 h) were transfected with DNMT3B expression plasmid, and the functions of cells with high
DNMT3B were evaluated in following experiments including migration, invasion, colony formation, and 3D
Matrigel growth assays.
DNMT3B siRNA 1 and DNMT3B siRNA 2 (Integrated
DNA Technologies, Inc., Coralville, IA) were also transfected into MDA-MB-231 and MDA-MB-436 cells.
Sequences of DNMT3B siRNA 1 and 2 can be seen in
Additional file 1: Table S1. After transfection for 48 h,
cells were collected and used for the in vitro cell culture
experiments listed below.
Cell proliferation assay

Cells which were transfected with anti-miR-29c and
miR-29c mimic (Origene, Rockville, MD) were seeded in
96-well plates at 2 × 103/well, respectively, and cultured
for 24, 48, 72, and 96 h. Ten microliters CCK-8
(Dojindo, Kumamoto, Japan) was added to the cells for
3–4 h, and their viability was measured at 450 nm using
SpectraMax M5 Microplate Reader, according to the
manufacturer’s instructions.
Cell migration and invasion assays

Briefly, 104 cells were plated on the top of transwells
with 8.0-μm pore polycarbonate membrane inserts
(Corning, New York, NY) for the migration assay. For
the invasion assay, the inserts were coated with a thin
layer of Matrigel basement membrane matrix (BD
Biosciences San Diego, CA). Serum (10%) was used as
the chemoattractant. After 24 h, the cells on the lower
surface of the inserts were fixed with methanol for
15 min, stained with 1% crystal violet solution for
15 min, and counted using a light microscope.
Soft agar colony formation assay and 3D Matrigel culture

The soft agar colony formation assay was performed
using 6-well plates. Each well contained 2 mL of 0.7%
agar in complete medium as the bottom layer and 1 mL
of 0.35% agar in complete medium containing 3000 cells
as the top layer. Cultures were then maintained under
standard culture conditions for 3–4 weeks. After culture, the colonies were stained with MTT solution
(200 μL/well), and the number of clones was
counted. The 3D cell culture was performed using
Matrigel matrix (BD Biosciences, San Diego, CA) in
96-well plates. Each well contained a mixture of
50 μL complete medium containing 1000 cells and
50 μL Matrigel matrix.
In silicon assay

To explore the expression of DNMT3B in breast cancer,
in silicon assay was carried out using data from
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Oncomine (www.oncomine.org) and TCGA. The database
from Oncomine is very useful for investigating genes that
are expressed in multiple cancer datasets to validate the
relationship between transcription and disease. More advanced analyses were used to check the expression of
genes in a small fraction of samples of a cancer type using
different filters.
To explore if survival rate of patients with breast cancers was associated with miR-29c or DNMT3B. Data online (OncoLnc: linking TCGA survival data to mRNAs,
miRNAs, and lncRNAs) was used. OncoLnc is available
at http://www.oncolnc.org. The plot of Kaplan-Meier
was automatically given using TCGA data when the special gene was decided and values of lower and higher
percentiles were input [26].
Western blot

Whole cell extracts were prepared from MCF-7 control
and MCF-7 transfected with anti-miR-29c, MDA-MB-231
control and MDA-MB-231 transfected with miR-29c
mimic, and MDA-MB-436 control and MDA-MB-436
transfected with miR-29c mimic and MDA-MB-231 transfected with DNMT3B siRNAs. In brief, cells were lysed in
radioimmunoprecipitation assay (RIPA) lysis buffer at 4 °C
for 30 min. The cell lysate was centrifuged at 12,000 rpm
for 10 min at 4 °C, and supernatant was collected. Protein
concentrations were determined by using the BCA Kit
(Beyotime, Guangzhou, China). Cell extracts were resolved by 10% SDS-PAGE, and the separated proteins
were transferred to a polyvinylidene difluoride membrane
(Millipore, Billerica, MA). The membranes were blocked
in 5% fat-free milk in TBS containing 0.1% Tween 20 for
1 h and then immunoblotted with primary antibodies with
appropriate dilutions overnight at 4 °C. The primary antibodies for staining included DNMT3B (Abcam, Cambridge, MA), TIMP3 (EMD Millipore, Billerica, MA),
STAT1 (Cell Signal, Boston, MA), and FOXO1 (Cell Signal, Boston, MA). After immunoblotting, the membranes
were washed three times with phosphate-buffered saline
with Tween (PBST) and followed by 1-h incubation with
horseradish peroxidase-conjugated goat anti-rabbit Ab
(1:5000, Santa Cruz Biotech, Santa Cruz, CA) or
horseradish peroxidase-conjugated rabbit anti-mouse
Ab (1:5000, Santa Cruz). The densities of protein
bands were quantified by Alpha Ease FCTM software
(Version 3.1.2, Alpha Innotech Corp, San Leandro, CA).
Quantitative reverse transcription PCR

Total extracted RNA (1 μg) was used for cDNA synthesis, with Oligo(dT) 20 primers (Invitrogen, Grand Island,
NY). The cDNA was added to a quantitative reverse
transcription-PCR mixture that contained 1× SYBR
Green PCR master mix (Quanta Biosciences, Gaithersburg,
MD) and 500 nmol/L gene-specific primers. Assays
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were performed in triplicate on a CFX thermocycler
(Bio-Rad, Hercules, CA). The primers are listed in
Additional file 1: Table S2.
Quantitative real-time methylation-specific PCR

The extraction of genomic DNA from breast cancer cells
(1 × 106) was performed using a QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Bisulfite modification was strictly carried out
according to the manufacturer’s instructions (Qiagen). The
methylation status of TIMP3 in specimens was assessed by
quantitative real-time methylation-specific PCR (qMSP)
using two sets of primers designed for methylated (M) or
unmethylated (U) DNA sequences using bisulfite-modified
DNA. The methylation-specific primers and unmethylatedspecific primers for the TIMP3 gene were designed according to the standard methods as described previously [27]
and are listed in Additional file 1: Table S3.
Immunohistochemistry

Five-micrometer paraffin-embedded tissue sections (35
tissues of breast cancers and 20 adjacent normal tissues)
were deparaffinized and rehydrated, antigens were retrieved, and IHC procedures were performed as reported
previously [28]. Briefly, the deparaffinized sections were
immersed in boiled 10 mM sodium citrate buffer (pH 6.0)
and maintained at sub-boiling temperature for 20 min.
After that, peroxidase activity was inactivated by incubation
with 3% H2O2 solution for 10 min at room temperature.
Then, the sections were incubated with primary DNMT3B
antibody (1:50 dilution; Abcam, Cambridge, MA) in a moist
chamber at 4 °C overnight. Negative controls were conducted by the exchange of primary antibody for PBS. Slides
were incubated with biotinylated anti-rabbit immunoglobulins for 60 min at room temperature and treated with
streptavidin-peroxidase (DAKO, Woodbridge, VA). Staining
was achieved by 3,3-diaminobenzidine (DAB; Vectastain,
Vector Laboratories, Inc., Linaris GmbH), and the slides
were counterstained with hematoxylin. Photographs were
taken with equal exposure on a Nikon Eclipse Ti microscope coupled with NIS elements software (Nikon,
Melville, NY) for Windows. Three visual fields were
randomly selected for the quantitative analysis which
was performed independently by two pathologists. The
semi-quantitative analysis of the stained sections was
done by light microscopy according to the immunoreactive score of Remmele and Stegner (IRS) [29, 30].
Luciferase reporter assay

DNMT3B luciferase reporters containing DNMT3B wildtype 3′UTR (CUCUUCUUACUGGUGCUA) or mutant
3′UTR (CUCUUCUUACUCCUCCUA) were purchased
from SWITCH Gear Genomics Company (Menlo Park,
CA). MDA-MB-231 cells were co-transfected with the
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50 ng luciferase reporter, 1 ng Renilla luciferase reporter
(pRL-CMV vector, Promega, Madison, WI), or/and
100 nM mimic miR-29c by Lipofectamine 3000 (Invitrogen, Grand Island, NY), respectively. After transfection for
24 h, cells were lysed and centrifuged at 12000 rpm for
10 min. The supernatant was collected following centrifuging, and luciferase activities were measured using the
Dual-Luciferase Assay System (Promega, Madison, WI).
The activity of Renilla luciferase was normalized to that of
firefly luciferase.
Statistical analysis

The results are given as mean ± SD. Student’s t test was
used to calculate the differences between the two study
groups. One-way ANOVA followed by LSD test was
used to calculate the differences among multiple study
groups. Fisher’s exact test was used to calculate the proportional differences of immunoreactive scores between
normal and tumor samples. Differences were considered
statistically significant at P < 0.05.

Results
The expression level of miR-29c was reduced in breast
cancer and was positively correlated with patient
survival rate

To assess the expression of miR-29c in breast cancer and
normal tissues, we extracted mRNA from breast cancer tissues and normal tissues and checked the expression of
miR-29c by qRT-PCR. As shown in Fig. 1a, the expression
of miR-29c was much lower in breast cancers than in normal tissues. We also examined the expression of miR-29c
in serum from breast cancer patients at different stages and
found that the expression of miR-29c in the serum was
decreased with the progression of breast cancers (Fig. 1b).
Furthermore, Kaplan-Meier meta-analyses of miR-29c
using online TCGA data (http://www.oncolnc.org) showed
that patients with high miR-29c expression had a higher
survival rate than patients with low miR-29c expression,
respectively (Fig. 1c).
Level of DNMT3B expression was upregulated in breast
cancer tissues and negatively correlated with the
survival rate

To investigate the expression of DNMT3B mRNA in
breast cancer tissues, publicly available expression data for
DNMT3B were retrieved from Oncomine and TCGA. Results showed that the expression level of DNMT3B
mRNA was upregulated in invasive breast carcinoma
(Fig. 2a, b), ductal breast carcinoma (Fig. 2c), and invasive ductal breast carcinoma (Fig. 2d).
The expression of DNMT3B mRNA and protein in
eight breast cancer tissues and eight adjacent non-tumor
tissues was assessed by qRT-PCR and Western blot. As
shown in Fig. 3a, b and Additional file 1: Figure S1, the
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Fig. 1 The expression of miR-29c was reduced in breast cancers and was positively correlated with the survival rate of breast cancer patients.
a The expression of miR-29c in normal tissues and breast cancer tissues was checked by qRT-PCR. b The expressions of miR-29c in the serum of
normal controls and breast cancer patients at different stages were evaluated by qRT-PCR. c Kaplan-Meier analysis of overall survival curves for
breast cancer patients with low versus high expressions of miR-29. Data were presented as mean ± SD, ***P < 0.001

Fig. 2 The data retrieved from Oncomine and TCGA showed that the expression of DNMT3B mRNA was increased in breast cancers. a Comparison of
the mRNA levels of DNMT3B in normal breast tissues (N = 61) and invasive breast carcinoma tissues (N = 389) using TCGA data retrieved from the
Oncomine database. b Comparison of the mRNA levels of DNMT3B in normal breast tissues (N = 4) and invasive breast carcinoma tissues (N = 154)
using Gluck’s data retrieved from the Oncomine database. c Comparison of the mRNA levels of DNMT3B in normal breast tissues (N = 7) and ductal
breast carcinoma tissues (N = 40) using Richardson’s data retrieved from the Oncomine database. d Comparison of the mRNA levels of DNMT3B in
normal breast tissues (N = 20) and invasive ductal breast carcinoma tissues (N = 5) using Turashvili’s data retrieved from the Oncomine database
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a

b

c

d

e

Fig. 3 DNMT3B expression was upregulated in breast cancers and was negatively correlated with the survival rate of breast cancer patients. a mRNA
levels of DNMT3B detected by qRT-PCR in eight breast cancer tissues were higher than that in their adjacent normal tissues. b Comparison of the
protein levels of DNMT3B in eight paired breast cancer and adjacent non-tumor tissues by Western blotting. c Immunohistochemistry representative
photos of DNTM3B expression in normal and different immunoreactive scores breast cancer tissues. d Immunoreactive scores of DNMT3B in breast
cancer and the adjacent normal tissues. e Kaplan-Meier analysis of overall survival curves for breast cancer patients with low versus high expression of
DNMT3B. Data were presented as mean ± SD, *P < 0.05, ***P < 0.001

expression level of DNMT3B mRNA and protein, respectively, was higher in breast cancers than in normal
breast tissues. To check the protein expression in breast
cancer tissues, IHC was carried out, and the results
showed that DNMT3B expression was higher in breast
cancers than that in normal breast tissues (Fig. 3c, d). In
addition, we performed in silico analysis using an online
TCGA database (http://www.oncolnc.org) and found
that breast cancer patients with high DNMT3B mRNA
expression had a lower survival rate than patients with
low DNMT3B mRNA expression (Fig. 3e).
miR-29c inhibited the proliferation, migration, and
invasion of breast cancer cells, which could be reversed
by the overexpression of DNMT3B

To explore the functional role of miR-29c in breast cell
lines, we performed loss- and gain-of-function analysis

in breast cancer cells. The knockdown of miR-29c in
MCF-7 cells increased cell proliferation (Fig. 4a) and
promoted the migration and invasion of cells (Fig. 4b,
Additional file 1: Figure S2). In contrast, the overexpression of miR-29c in MDA-MB-231 and MDA-MB-436 cells
reduced cell proliferation (Fig. 4c and Additional file 1:
Figure S3) and inhibited the migration and invasion of
cells (Fig. 4d, Additional file 1: Figures S2 and S3).
To determine whether miR-29c-induced inhibition of cell
migration and invasion could be reversed by restoration of
DNMT3B expression, we performed gain-of-function analysis in MDA-MB-231 miR-29c cells. Results showed that
the overexpression of DNMT3B in MDA-MB-231 miR29c cells promoted cell migration and invasion of cells
(Additional file 1: Figure S4), which suggested that miR29c-induced inhibition of cell migration and invasion
could be reversed by the overexpression of DNMT3B.
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Fig. 4 miR-29c inhibited the proliferation, migration and invasion, colony formation, and growth in 3D Matrigel of breast cancer cells. a Proliferation of
MCF-7 anti-miR-29c is higher than that of MCF-7 Cntl by CCK8 proliferation assay. b Migration and invasion of MCF-7 anti-miR-29cis higher than that of
MCF-7 Cntl. c Proliferation of MDA-MB-231 miR-29c mimic is lower than that MDA-MB-231 Cntl by CCK8 proliferation assay. d Migration and invasion
assays of MDA-MB-231 miR-29c mimic are lower than that MDA-MB-231 Cntl. e Colony formations of MCF-7 anti-miR-29c are more than that of MCF-7
Cntl in Soft agar assays. f Growth of MCF-7 anti-miR-29c is more than that of MCF-7 Cntl in 3D Matrigel culture. g Colony formations of MDA-MB-231
miR-29c mimic are less than that of MDA-MB-231 Cntl in soft agar assays. h Growth of MDA-MB-231 miR-29c mimic is less than that of MDA-MB-231
Cntl in 3D Matrigel culture. Data are presented as mean ± SD from three independent experiments, and every experiment was repeated three
times, *P < 0.05

miR-29c inhibited colony formation and growth in breast
cancer cells

To investigate the role of miR-29c in the tumorigenesis of
breast cancer cells, soft agar and 3D Matrigel culture of
MCF-7 Cntl, MCF-7 anti-miR-29c, MDA-MB-231 Cntl,
MDA-MB-231 miR-29c, MDA-MB-436Cntl, and MDAMB-436 miR-29c were carried out. Results showed that
the knockdown of miR-29c in MCF-7 cells facilitated the
colony formation and growth (Fig. 4e, f and Additional file 1:
Figure S5), whereas the overexpression of miR-29c in

MDA-MB-231 and MDA-MB-436 cells reduced the
colony formation and growth in both soft agar (Fig. 4g,
Additional file 1: Figures S3 and S5) and 3D Matrigel
cultures (Fig. 4h and Additional file 1: Figure S3).
To determine whether miR-29c-induced the inhibition
of tumorigenesis could be reversed by restoration of
DNMT3B expression, we performed gain-of-function
analysis in MDA-MB-231 miR-29c cells. The overexpression of DNMT3B in MDA-MB-231 miR-29c cells facilitated the colony formation and growth in both soft
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agar and 3D Matrigel cultures (Additional file 1: Figure S4),
which suggested that miR-29c-induced inhibition of colony
formation and growth in 3D Matrigel could be reversed by
the overexpression of DNMT3B.
DNMT3B is directly targeted by miR-29c

Previous study showed that miR-29c was negatively correlated with the expression of DNMT3B in melanoma in
our group [18]. In breast cancers, DNMT3B was also
post-transcriptionally regulated by miRNAs [17, 31]. To
explore the relationship between DNMT3B and miR29c, an in silico assay was performed to investigate
whether miR-29c could bind to the 3′UTR of DNMT3B
(http://www.targetscan.org/, http://www.mirbase.org). This
analysis identified a conserved sequence UGGUGCU is the
3′UTR as a potential binding site for miR-29c (Fig. 5a). To
further verify that DNMT3B is the target of miR-29c, luciferase reporter plasmids containing conserved or mutated
sequences UCCUCCU of DNMT3B were co-transfected
with miR-29c mimic in MDA-MB-231 cells. As shown in
Fig. 5b, the luciferase activity caused by DNMT3B 3′UTR
(wild-type) was significantly reduced by miR-29c, while the
luciferase activity caused by DNMT3B 3′UTR (mutation)
was not reduced by miR-29c. The luciferase assay was also
carried out in MCF-7 cell, and similar results were found
(shown in Additional file 1: Figure S6). The expression of
DNMT3B protein was reduced by overexpression of miR29c while the expression of DNMT3B protein was increased by inhibition of miR-29c expression (Fig. 5c, e).
These results suggest that miR-29c binds the 3′UTR of
DNMT3B and regulates the expression of DNMT3B.
miR-29c inhibits breast cancer cells by targeting the
DNMT3B/TIMP3/STAT1/FOXO1 pathway

TIMP3 plays a role as a tumor suppressor in many cancers. Methylation of TIMP3 has been found in several
cancers [32, 33]. Since DNMT3B is a major DNA methyltransferase, regulated by miR-29c, we investigated
TIMP3 methylation and the expression in MDA-MB231 cells with miR-29c overexpression and MCF-7 cells
with miR-29c knockdown. Methylation of TIMP3 was
increased, whereas the protein level of TIMP3 was reduced in MCF-7 cells with miR-29c knockdown compared
to control (Fig. 5c, d, Additional file 1: Figure S7B). On the
contrary, methylation of TIMP3 was reduced, and the protein level of TIMP3 was increased in MDA-MB-231 with
miR-29c overexpression compared to control (Fig. 5e, f,
Additional file 1: Figure S7F). STAT1 and FOXO1 are
downstream targets of TIMP3. To confirm that miR-29c
exerts its function on breast cancer by STAT1/FOXO1
pathway, the protein levels of STAT1 and FOXO1 were
checked in MDA-MB-231 cells with miR-29c overexpression and MCF-7 cells with miR-29c knockdown. As shown
in Fig. 5c, e and Additional file 1: Figures S7C and S5D, the
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protein expression of STAT1 was increased while the expression of FOXO1 was reduced in MCF-7 cells with miR29c knockdown compared to control. On the contrary, the
protein expression of STAT1 was reduced while the
protein expression of FOXO1 was increased in MDAMB-231 with miR-29c overexpression compared to
control (Fig. 5c, e, Additional file 1: Figures S7G and
S7H. In addition, pretreatment of cells with fludarabine,
a specific inhibitor of STAT1 activation but not of other
STATs, abrogated the increment of migration and invasion
caused by miR-29c inhibition in MCF-7 cells (Fig. 5g, h).
Furthermore, pretreatment of fludarabine blocked the
changes in expression of STAT1 and FOXO1 caused by
miR-29c inhibition in MCF-7 cells (Fig. 5i). All together,
these results suggest that miR-29c inhibits breast cancer by targeting the DNMT3B/TIMP3/STAT1/FOXO1
pathway (Fig. 7).
Knockdown of DNMT3B by siRNA reduced the
proliferation, migration, and invasion

To check whether DNMT3B protein expression affected
cell proliferation, migration, and invasion, MDA-MB-231
and MDA-MB-436 were transfected with DNMT3B siRNAs. As shown in Fig. 6a–d, DNMT3B protein expression
was significantly reduced by both DNMT3B siRNA 1 and
DNMT3B siRNA 2 in MDA-MB-231 and MDA-MB-436
cells. Knockdown of DNMT3B by siRNA reduced proliferation, migration, and invasion of MDA-MB-231 and MDAMB-436 cells, respectively (Fig. 6e–h, Additional file 1:
Figure S8). These results suggest that DNMT3B played an
important role in the functions of breast cancer cells.

Discussion
Breast cancer is a heterogeneous disease, both biologically and clinically. More and more evidence supports the
notion that microRNAs (miRNAs) play a critical role as
oncogenes or as tumor suppressor genes in cancers.
miR-29c is significantly downregulated in many cancers
including breast cancer, suggesting that miR-29c acts as
a suppressor miRNA in cancers. However, the functional
role and underlying mechanism of miR-29c action in
breast cancer have not been elucidated. In this study, we
investigated the function of miR-29c and explored its
underlying mechanism in breast cancers. We firstly reported that miR-29c plays a significant role in suppressing
the progression of breast cancers by targeting the TIMP3/
STAT1/FOXO1 pathway. Our results also showed there
was a lower miR-29c expression in breast cancers than
that in normal tissues and that overexpression of miR-29c
inhibited cell proliferation, migration and invasion of cells,
colony formation, and growth in 3D Matrigel. In addition,
we identified that miR-29c directly targets DNMT3B and
inhibited expression of DNMT3B which was associated
with methylation of TIMP3.
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Fig. 5 miR-29c directly targeted DNMT3B and regulated the DNMT3B/TIMP3/STAT1/FOXO1 pathway in breast cancer cells. a The potential binding
site of miR-29c in the 3′UTR of DNMT3B. b Dual-Luciferase Reporter Assay of miR-29c and DNMT3B in MDA-MB-231 cells. c Protein levels of DNMT3B,
TIMP3, STAT1, and FOXO1 detected by Western blotting in MCF-7 cells after the transfection of miR-29c inhibitor. d qMS-PCR assay of the methylation
level of TIMP3 in MCF-7 cells after the transfection of miR-29c inhibitor. e Protein levels of DNMT3B, TIMP3, STAT1, and FOXO1 detected by Western
blotting in MDA-MB-231 cells after the transfection of miR-29c mimic. f qMS-PCR assay of the methylation level of TIMP3 in MDA-MB-231 cells
after the transfection of miR-29c mimic. g Migration assays of MCF-7 cells that were co-treated with fludarabine (STAT1 inhibitor) and miR-29c
inhibitor. h Invasion assays of MCF-7 cells that were co-treated with fludarabine (STAT1 inhibitor) and miR-29c inhibitor. i Protein levels of
STAT1 and FOXO1 detected by Western blotting in MCF-7 cells that were co-treated with fludarabine (STAT1 inhibitor) and miR-29c inhibitor.
Data are presented as mean ± SD from three independent experiments, and every experiment was repeated three times, *P < 0.05, ***P < 0.001

It was reported that miR-29c-5p expression was upregulated in breast cancers with the luminal subtypes [34].
Elizabeth Poli et al. reported that MicroRNA-29c (miR-29c)
has been shown to be significantly downregulated in basallike breast tumors and to be involved in cell invasion and
sensitivity to chemotherapy [16]. Study showed that there
was significantly reduced expression of miR-29c in basal-

like breast cancers compared to other breast cancer molecular subtypes and that miR-29c was associated with
DNMT3B and methylation of genes [17]. Study showed
that miR-29c efficiently downregulated B7-H3 expression
and the expression of miR-29c correlated with survival
rate of breast cancer patients, suggesting a tumor suppressive role of miR-29c [35]. Our results showed that there
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Fig. 6 Knockdown of DNMT3B inhibited the proliferation, migration, and invasion in MDA-MB-231 and MDA-MB-436 cells. a Protein levels of DNMT3B
detected by Western blotting in MDA-MB-231 cells after the transfection of DNMT3B siRNA 1 and 2. b Protein levels of DNMT3B detected by Western
blotting in MDA-MB-436 cells after the transfection of DNMT3B siRNA 1 and 2. c Quantification of DNMT3B protein levels in MDA-MB-231 cells after
the transfection of DNMT3B siRNA 1 and 2. d Quantification of DNMT3B protein levels in MDA-MB-436 cells after the transfection of DNMT3B siRNA 1
and 2. e CCK-8 proliferation assays of MDA-MB-231 cells after the transfection of DNMT3B siRNA. f CCK-8 proliferation assays of MDA-MB-436 cells after
the transfection of DNMT3B siRNA. g Migration and invasion assays of MDA-MB-231 cells after the transfection of DNMT3B siRNA. h Migration and
invasion assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. Data are presented as mean ± SD from three independent experiments,
and every experiment was repeated three times

was a different expression level of miR-29c in breast cancer
cells with different subtypes. MCF-7 is a breast cancer cell
line with ER positive. MDA-MB-231 is a breast cancer cell
line with ER negative, PR negative, and HER2 negative).
Our results further confirmed that the expression of miR29c was associated with the subtype of breast cancers,
grades of cancer, methylation of genes in breast cancers,
and survival rate of patients with breast cancers. miR-29c

was found to exert a suppressive role in the development of
breast cancers. These results can be very useful to identify
miR-29c as a biomarker of diagnosis and therapy in breast
cancers.
DNA methyltransferases, including DNMT1, DNMT3A,
and DNMT3B, are enzymes that catalyze DNA methylation. DNMT3A and DNMT3B are mainly involved in de
novo DNA methylation, whereas DNMT1 is required for
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the maintenance of pre-existing methylation [36]. In cancer tissues, DNMT3B is expressed more frequently compared to DNMT1 and DNMT3A [37]. In breast cancer,
DNMT3B is also frequently overexpressed [24, 25]. We
did in silico analysis using the Oncomine database (www.
oncomine.org) and found that the expression level of
DNMT3B was higher in invasive ductal breast carcinomas
than in normal tissues, confirming previous results. miRNAs, acting as post-transcriptional regulators, can directly
degrade target mRNAs and/or repress their translation in
a sequence-specific manner [38]. Our previous study
showed that miR-29c was negatively correlated with the
expression of DNMT3B in melanoma [18]. Here, we demonstrated that miR-29c targeted the 3′UTR of DNMT3B
and inhibited its expression, and that both miR-29c expression and DNMT3B expression were associated with
the survival rate of patients with breast cancer.
Methylation of gene promoters increases with the progression of cancers [39, 40]. DNMT3B is overexpressed
and is involved in the methylation of genes in cancers
[18]. One of the major mechanisms of the carcinogenesis
process is thought to be the inactivation of tumor suppressor genes by the methylation of their promoter regions. Abnormal expression of DNMT3B is related to the
hypermethylation of the tumor suppressor genes. TIMP3
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is an inhibitor of extracellular matrix metalloproteinase
that can suppress angiogenesis [41, 42], tumor growth
[43, 44], and invasion and migration [43–45]. It has
been reported that in many common tumors, CpG islands
of TIMP3 undergo methylation frequently [46, 47] and
that in the primary tumors, the methylation of the TIMP3
promoter can lead to the loss of its protein expression
[48]. Moreover, treating methylated human gastric cancer
cell lines with 5-aza can even rescue the defective expression of TIMP3 [49]. These studies suggest that epigenetic
changes in tumors may play an important role in regulating TIMP3 expression [50]. miR-29c regulated DNMT3B
which was associated with methylation of genes in breast
cancers [17]. There is a lower level of miR-29c expression
in hypermethylator breast cancer cell lines than nonhypermethylator breast cancer cell lines. The expression of
miR-29c correlated inversely with methylation-sensitive
gene expression and directly with the methylation status of
these genes [31]. In this study, methylation of the TIMP3
promoter and changes in expression of TIMP3 and
DNMT3B were all affected by miR-29c regulation. In
addition, the direct binding of miR-29c to the wild-type 3′
UTR of DNTM3B indicates that miR-29c is the direct
post-transcriptional regulator of DNMT3B, which is elevated in breast cancer and methylates the promoter of the

Fig. 7 Proposed mechanistic scheme: miR-29c suppresses breast cancer by the TIMP3/STAT1/FOXO1 pathway. The expression of miR-29c was
decreased in breast cancer, which leading to the elevated expression of DNMT3B that is critical for promoter methylation and decreases the
expression of TIMP3. As a result, the expression of STAT1 was increased, and it inhibits the expression of FOXO1, leading to proliferation, migration, and
invasion of breast cancer cells
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TIMP3 gene. Taken together, our results support the concept that the expression of TIMP3 is ultimately regulated
by miR-29c.
Signal transducer and activator of transcription 1
(STAT1) is a member of the STAT protein family, which
plays important roles in cancer inflammation. STAT1
was associated with cancers, especially in breast cancers
[51]. In tumor microenvironment, tumor-induced stromal STAT1 increased the progression of breast cancer
via deregulating tissue homeostasis [52]. STAT1 can promote the growth of breast cancer by inhibiting immunity
[53]. Inhibition of STAT1 signaling reduced the primary
growth and progression of breast cancer cells [54].
When activated via phosphorylation at the Tyr701 site,
STAT1 binds specific regulatory elementary and regulates the transcription of its target genes [55]. Forkhead
box protein O1 (FOXO1) belongs to the forkhead family
of transcription factors which are characterized by a distinct forkhead domain and play many important roles in
cancers [56]. FOXO1 was considered as tumor suppressor gene. The RNA-binding protein Quaking (QKI) resulted in low levels of FOXO1 expression in breast cancer
cells [57]. Astrocyte-elevated gene-1 (AEG-1) inhibited
the expression of FOXO1 and promoted the progression
of breast cancer [58]. Acylglycerol kinase was reported to
promote the growth of cells and tumorigenicity in breast
cancer by inhibiting the expression of FOXO1 [59].TIMP3
is a versatile extracellular regulator in cancers [60]. The
loss of TIMP3 can lead to diabetic kidney disease in both
human and mouse via the interplay of FOXO1 and STAT1
[61]. In addition, miR-29c is involved in diabetic nephropathy by targeting tristetraprolin [62]. However, it is unclear
that TIMP3 inhibits the progress of breast cancer via the
FOXO1/STAT1 pathway. We show that the expression of
TIMP3 and FOXO1 is decreased whereas the expression
of STAT1 is increased in miR-29c knockdown MCF-7
cells. STAT1 has been reported to exhibit a negative regulatory effect on FOXO1 transcription in pancreatic β cells
[61] and bladder cancer [63]. Fludarabine is a specific inhibitor of STAT1 [64]. Fludarabine inhibited the decrease
of FOXO1 expression caused by knockdown of miR-29c
and abrogated the increment of cell migration and invasion
caused by knockdown of miR-29c. We firstly illustrated that
miR-29c exerted its regulatory function in breast cancers by
activating the TIMP3/STAT1/FOXO1 pathway. This is
firstly reported that miR-29c inhibited the proliferation, migration, invasion colony, and 3D growth of breast cancer
cells by targeting TIMP3/STAT1/FOXO1 pathway.

Conclusion
In conclusion, we found that the expression of miR-29c
is correlated with the progress and prognosis of breast
cancers. DNMT3B is a direct target of miR-29c. DNMT3B
expression increases as miR-29c expression decreases in
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cells. Upregulated DNMT3B is critical for promoter
methylation and decreased expression of TIMP3, which
could promote progression of breast cancer via the
TIMP3/STAT1/FOXO1 pathway (Fig. 7). These results
suggest that miR-29c could be used as a potential biomarker of diagnosis and therapy in breast cancers.
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